Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

BioArctic stock

BIOA B.ST
SE0010323311
A2H5GS

Price

204.49
Today +/-
-0.44
Today %
-2.47 %

BioArctic stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the BioArctic stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the BioArctic stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the BioArctic stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze BioArctic's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

BioArctic Stock Price History

DateBioArctic Price
1/8/2025204.49 undefined
1/7/2025209.60 undefined
1/3/2025212.00 undefined
1/2/2025209.80 undefined
12/30/2024199.50 undefined
12/27/2024203.60 undefined
12/23/2024202.00 undefined
12/20/2024212.80 undefined
12/19/2024220.20 undefined
12/18/2024170.00 undefined
12/17/2024171.60 undefined
12/16/2024173.20 undefined
12/13/2024171.80 undefined
12/12/2024174.90 undefined
12/11/2024180.20 undefined
12/10/2024180.30 undefined

BioArctic Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into BioArctic, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BioArctic from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BioArctic’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of BioArctic. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into BioArctic’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing BioArctic’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BioArctic’s growth potential.

BioArctic Revenue, EBIT and net profit per share

DateBioArctic RevenueBioArctic EBITBioArctic Net Income
2029e6.79 B undefined5.85 B undefined3.87 B undefined
2028e4.91 B undefined4.04 B undefined2.68 B undefined
2027e2.82 B undefined2.05 B undefined1.37 B undefined
2026e1.72 B undefined918.62 M undefined669.94 M undefined
2025e1.02 B undefined332.05 M undefined228.25 M undefined
2024e269.04 M undefined-237.9 M undefined-177.81 M undefined
2023616 M undefined264.58 M undefined229.25 M undefined
2022228.29 M undefined-7.94 M undefined-11.18 M undefined
202123.15 M undefined-140.74 M undefined-119.79 M undefined
202062.35 M undefined-85.67 M undefined-68.52 M undefined
2019281.77 M undefined111.09 M undefined88.47 M undefined
2018713.97 M undefined485.83 M undefined381.6 M undefined
2017140.71 M undefined19.29 M undefined15.16 M undefined
2016105.61 M undefined62.68 M undefined57.58 M undefined
201541.57 M undefined4.82 M undefined3.71 M undefined

BioArctic Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0.040.110.140.710.280.060.020.230.620.271.021.722.824.916.79
-156.1033.33409.29-60.59-77.94-62.90891.30169.74-56.26278.4469.2563.4974.3038.23
100.00100.0074.2995.6588.9761.29-4.3585.5391.87210.0455.5032.7920.0611.518.32
4110510468225038-1195565000000
00.060.020.380.09-0.07-0.12-0.010.23-0.180.230.671.372.683.87
-1,800.00-73.682,440.00-76.90-177.2775.00-90.76-2,181.82-177.29-228.81193.42105.3895.0544.48
88.0663.0668.0688.1388.0688.0688.0685.9988.49000000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The BioArctic Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the BioArctic is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
20162017201820192020202120222023
               
0.691.110.921.1110.850.811.11
0.63000.1902.8400.22
1.760018.485.66.217.966.88
00000000
4.5620.12460.8512.952.824.347.534.06
0.71.131.381.141.010.860.821.15
5.647.099.2937.1339.9433.7535.2631.13
2.682.681.51.511.561.591.611.65
000006.27.960
001.500000
00000000
172229189298451608596567
8.491012.4838.9441.9542.1445.4333.34
0.711.141.391.181.050.90.871.19
               
0.111.761.761.761.761.761.761.77
00000560.025660
0.060.070.560.560.560.790.781.04
0.96560.98455.96412.72345.520.960.960.96
00000000
0.060.641.020.970.911.351.351.05
11.747.5914.818.2214.3111.8221.4929.87
00000030.7642.96
631.34491.28327.98134.5787.2781.369.7749.32
00000000
0006.447.148.098.862.83
643.08498.86342.79149.22108.72101.2770.88124.97
00020.9313.637.791.182.15
4.145.4932.5238.6920.670012.39
00-000000
4.145.4932.5259.6134.297.791.1814.54
647.22504.35375.31208.83143.01109.0572.07139.5
0.711.141.391.181.051.461.421.19
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of BioArctic provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand BioArctic's financial health and stability.

Assets

BioArctic's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that BioArctic must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of BioArctic after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into BioArctic's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
47419488112-85-139-17252
1112000140
000000000
0620-113832212-52737
-22-21-145-728-107-195-559
0001,0001,0001,000000
007108012000
-16675-135-200327-92-140-31299
-2-2-3-4-3-12-4-120
-2-2-2-3-3-12-4-12-506
0001,0000000-506,000
000000000
0000-6-6-7-80
00560000050
0-1055600-138-6-7-214
0000000014
0-10500-1320000
-18578417-193195-112-151-43-193
-18.73672.16-138.78-204.31323.9-104.81-144.84-44.38299.03
000000000

BioArctic stock margins

The BioArctic margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioArctic. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioArctic.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the BioArctic's sales revenue. A higher gross margin percentage indicates that the BioArctic retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the BioArctic's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the BioArctic's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BioArctic's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BioArctic. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BioArctic's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

BioArctic Margin History

BioArctic Gross marginBioArctic Profit marginBioArctic EBIT marginBioArctic Profit margin
2029e91.73 %86.14 %57.05 %
2028e91.73 %82.2 %54.59 %
2027e91.73 %72.89 %48.78 %
2026e91.73 %53.32 %38.88 %
2025e91.73 %32.62 %22.42 %
2024e91.73 %-88.43 %-66.09 %
202391.73 %42.95 %37.22 %
202285.54 %-3.48 %-4.9 %
2021-7.37 %-608.05 %-517.54 %
202062.52 %-137.41 %-109.9 %
201988.94 %39.42 %31.4 %
201895.53 %68.05 %53.45 %
201774.27 %13.71 %10.77 %
201699.77 %59.35 %54.52 %
2015100 %11.6 %8.92 %

BioArctic Stock Sales Revenue, EBIT, Earnings per Share

The BioArctic earnings per share therefore indicates how much revenue BioArctic has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue BioArctic earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates BioArctic's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of BioArctic’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BioArctic's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

BioArctic Revenue, EBIT and net profit per share

DateBioArctic Sales per ShareBioArctic EBIT per shareBioArctic Earnings per Share
2029e92.14 undefined0 undefined52.57 undefined
2028e66.66 undefined0 undefined36.39 undefined
2027e38.26 undefined0 undefined18.66 undefined
2026e23.39 undefined0 undefined9.1 undefined
2025e13.82 undefined0 undefined3.1 undefined
2024e3.65 undefined0 undefined-2.41 undefined
20236.96 undefined2.99 undefined2.59 undefined
20222.65 undefined-0.09 undefined-0.13 undefined
20210.26 undefined-1.6 undefined-1.36 undefined
20200.71 undefined-0.97 undefined-0.78 undefined
20193.2 undefined1.26 undefined1 undefined
20188.1 undefined5.51 undefined4.33 undefined
20172.07 undefined0.28 undefined0.22 undefined
20161.67 undefined0.99 undefined0.91 undefined
20150.47 undefined0.05 undefined0.04 undefined

BioArctic business model

BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.com.

BioArctic SWOT Analysis

Strengths

BioArctic AB benefits from several strengths that contribute to its success in the market. These include:

  • Strong expertise in biotechnology and neuroscience research
  • Robust portfolio of innovative therapies and products
  • Positive reputation and recognition in the industry
  • Strong intellectual property protection for its discoveries
  • Well-established collaborations with reputable organizations

Weaknesses

Despite its strengths, BioArctic AB also faces certain weaknesses that could pose challenges to its growth and competitiveness:

  • Relatively small size compared to some competitors
  • Dependence on a limited number of key partnerships
  • High research and development costs
  • Need for continuous innovation to stay ahead in a dynamic industry
  • Limited market reach in certain geographic regions

Opportunities

BioArctic AB can leverage various opportunities to further expand its market presence and achieve sustainable growth:

  • Rising demand for novel therapies targeting neurodegenerative diseases
  • Exploring emerging markets with unmet medical needs
  • Potential partnerships and collaborations to enhance research capabilities
  • Advancements in technology for improved drug delivery systems
  • Growing support from regulatory authorities for innovative treatments

Threats

BioArctic AB should be wary of potential threats that could impact its business operations and future prospects:

  • Intense competition from larger pharmaceutical companies
  • Uncertainty in regulatory approval processes
  • Rapidly evolving market trends and customer preferences
  • Potential patent challenges and intellectual property disputes
  • Economic fluctuations and market volatility
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

BioArctic Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

BioArctic historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

BioArctic shares outstanding

The number of shares was BioArctic in 2024 — This indicates how many shares 88.487 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue BioArctic earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates BioArctic's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of BioArctic’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BioArctic's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

BioArctic dividend history and estimates

In 2024, BioArctic paid a dividend amounting to 0 SEK. Dividend means that BioArctic distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for BioArctic provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify BioArctic’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating BioArctic's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

BioArctic Dividend History

DateBioArctic Dividend
2029e78.49 undefined
2028e54.34 undefined
2027e27.87 undefined
2026e13.58 undefined
2025e4.63 undefined
2024e-3.6 undefined
20191.5 undefined

BioArctic dividend payout ratio

In 2024, BioArctic had a payout ratio of 149.31%. The payout ratio indicates the percentage of the company's profits that BioArctic distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for BioArctic represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for BioArctic could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate BioArctic's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

BioArctic Payout Ratio History

DateBioArctic Payout ratio
2029e149.31 %
2028e149.31 %
2027e149.31 %
2026e149.31 %
2025e149.31 %
2024e149.31 %
2023149.31 %
2022149.31 %
2021149.31 %
2020149.31 %
2019149.31 %
2018149.31 %
2017149.31 %
2016149.31 %
2015149.31 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for BioArctic.

BioArctic latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.52 -0.22  (57.84 %)2024 Q3
6/30/2024-0.78 -0.77  (0.99 %)2024 Q2
3/31/2024-0.75 -0.65  (13.8 %)2024 Q1
12/31/2023-0.8 -0.99  (-23.55 %)2023 Q4
9/30/20230.93 1.41  (50.92 %)2023 Q3
6/30/2023-0.95 -1.16  (-22.18 %)2023 Q2
12/31/2022-0.83 -0.66  (20.31 %)2022 Q4
9/30/20221.75 1.54  (-11.86 %)2022 Q3
6/30/2022-0.01 -0.52  (-5,048.51 %)2022 Q2
3/31/2022-0.54 -0.5  (6.59 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the BioArctic stock

Eulerpool World ESG Rating (EESG©)

75/ 100

🌱 Environment

87

👫 Social

97

🏛️ Governance

42

Environment

Scope 1 - Direct Emissions
5.81
Scope 2 - Indirect emissions from purchased energy
7.278
Scope 3 - Indirect emissions within the value chain
49.761
Total CO₂ emissions
13.088
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees63
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

BioArctic shareholders

%
Name
Stocks
Change
Date
28.35332 % Demban AB20,885,05204/30/2024
18.11458 % Ackelsta AB13,343,20104/30/2024
6.61378 % Fj¿rde AP-Fonden4,871,714100,0004/30/2024
4.54572 % Tredje AP Fonden3,348,37851,29012/31/2023
4.23260 % RA Capital Management, LP3,117,73604/30/2024
3.24115 % Swedbank Robur Fonder AB2,387,433-744,4164/30/2024
2.97837 % Handelsbanken Kapitalf¿rvaltning AB2,193,86710,3509/30/2024
2.97343 % Nordea Funds Oy2,190,225360,0684/30/2024
2.19787 % Unionen1,618,9508,7274/30/2024
1.67968 % The Vanguard Group, Inc.1,237,2501,3734/30/2024
1
2
3
4
5
...
10

BioArctic Executives and Management Board

Ms. Gunilla Osswald

(62)
BioArctic Chief Executive Officer
Compensation 8.73 M

Mr. Lars Lannfelt

(74)
BioArctic Director, Senior Vice President University Collaborations (since 2017)
Compensation 2.45 M

Mr. Ivar Verner

(76)
BioArctic Independent Deputy Chairman of the Board
Compensation 400,000

Dr. Eugen Steiner

(68)
BioArctic Independent Chairman of the Board
Compensation 350,000

Mr. Par Gellerfors

(76)
BioArctic Director
Compensation 321,000
1
2
3
4

Most common questions regarding BioArctic

What values and corporate philosophy does BioArctic represent?

BioArctic AB represents values of innovative research, scientific excellence, and patient-centric approach. With a strong corporate philosophy focused on enhancing the quality of life for patients, BioArctic is dedicated to developing breakthrough treatments for debilitating disorders. By combining expertise in neuroscience and antibody technologies, BioArctic aims to create novel therapeutics and diagnostics for diseases like Alzheimer's and Parkinson's. The company prioritizes integrity, collaboration, and ethical conduct, striving to make a positive impact on society. BioArctic's commitment to scientific advancement and improving patients' well-being has cemented its position as a leading player in the field of biotechnology.

In which countries and regions is BioArctic primarily present?

BioArctic AB is primarily present in Sweden, where its headquarters are located. The company has a significant presence in the Nordic region, including Norway, Denmark, Finland, and Iceland. Additionally, BioArctic AB has expanded its presence globally, with operations and partnerships in various countries and regions. The company's focus on innovative drug development and research has allowed it to establish a strong presence in the biotechnology and pharmaceutical industries on an international scale.

What significant milestones has the company BioArctic achieved?

BioArctic AB has achieved several significant milestones. The company successfully developed and received regulatory approvals for its innovative drug candidate, Aduhelm, for the treatment of Alzheimer's disease. In addition, BioArctic AB entered into collaboration agreements with major pharmaceutical companies, such as Eisai and AbbVie, to further advance its product pipeline. The company also achieved positive clinical trial results for its Parkinson's disease drug candidate, BAN2401. Furthermore, BioArctic AB successfully listed on the Nasdaq Stockholm stock exchange, further enhancing its visibility and access to capital markets. These achievements highlight BioArctic AB's commitment to advancing groundbreaking therapies and its strong position in the biopharmaceutical industry.

What is the history and background of the company BioArctic?

BioArctic AB is a Swedish biopharmaceutical company specializing in the research and development of innovative treatments for neurological disorders. Established in 2003, BioArctic has grown into a leading player in the industry, focusing on diseases such as Alzheimer's and Parkinson's. With a strong commitment to enhancing the quality of life for patients, BioArctic combines cutting-edge science and technology to develop novel therapies. The company has an extensive portfolio of proprietary technologies and partnerships with prominent pharmaceutical companies. BioArctic's dedication to advancing neuroscience and delivering life-changing solutions has positioned it as a key player in the field of neurological research and development.

Who are the main competitors of BioArctic in the market?

The main competitors of BioArctic AB in the market include companies such as Biogen Inc., Eli Lilly and Company, and AbbVie Inc. These companies operate in the biopharmaceutical industry and have a similar focus on developing treatments for neurological disorders like Alzheimer's disease, where BioArctic AB specializes. These competitors have their own portfolios of potential drug candidates and are actively engaged in research and development efforts. However, BioArctic AB distinguishes itself through its innovative approaches and collaborations with other pharmaceutical companies, which contribute to its unique position in the market.

In which industries is BioArctic primarily active?

BioArctic AB is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of BioArctic?

The business model of BioArctic AB revolves around developing innovative therapies for debilitating neurological disorders. The company specializes in researching, developing, and commercializing drugs based on antibodies and small molecules. BioArctic AB primarily focuses on addressing neurodegenerative diseases like Alzheimer's and Parkinson's by developing disease-modifying treatments. With a strong emphasis on scientific expertise and collaboration with academic institutions, the company aims to bring novel therapies to market that can improve the quality of life for patients and their families. As a result, BioArctic AB is dedicated to driving advancements in neurodegenerative disease research and providing effective treatment options for those in need.

What is the P/E ratio of BioArctic 2025?

The BioArctic P/E ratio is 79.28.

What is the P/S ratio of BioArctic 2025?

The BioArctic P/S ratio is 17.77.

What is the Quality Investing of BioArctic?

The Quality Investing for BioArctic is 4/10.

What is the revenue of BioArctic 2025?

The expected BioArctic revenue is 1.02 B SEK.

How high is the profit of BioArctic 2025?

The expected BioArctic profit is 228.25 M SEK.

What is the business model of BioArctic

BioArctic AB is a Swedish biotechnology company specializing in the development of therapeutics for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company was founded in 2003 and is headquartered in Stockholm, Sweden. The business model of BioArctic is based on three main areas: 1. Product development BioArctic is working on developing new and innovative therapeutic solutions for neurodegenerative diseases. The company collaborates closely with leading scientists and experts in the field to develop new inhibitors and antibodies that can protect the nervous system and stop degenerative processes. An important part of BioArctic's product development process is the clinical phase. The company conducts clinical trials on patients to test the effectiveness of these therapeutics and ensure their safety. 2. Licensing and partnerships BioArctic is also active in the licensing and partnerships space. The company collaborates with other biotechnology or pharmaceutical companies that have an interest in its technologies and products. This allows BioArctic to share its research and development costs and expand its reach in the market. Through partnerships with other companies, BioArctic can also gain access to exclusive technologies and know-how that complement its own capabilities and increase its competitiveness. 3. Licensing out In addition to partnering and collaborating with other companies, BioArctic also licenses its own technologies and products to other companies. The company has already licensed its technology to several companies in the United States, Europe, and Asia. BioArctic's products are highly innovative and unique. The company's flagship product is Aduhelm, an antibody against beta-amyloid plaques that accumulate in the brain and can lead to Alzheimer's disease. Aduhelm was approved by the U.S. Food and Drug Administration (FDA) in June 2021 for the treatment of Alzheimer's disease. BioArctic receives a licensing fee and/or royalties for the use of its technology and the commercial exploitation of the product by the licensed companies. In addition to Aduhelm, BioArctic is also developing other innovative therapeutics such as BAN0805, which aims to degrade alpha-synuclein in the brain fluid. These products are still in development and require further clinical trials before they can be brought to market. In conclusion, BioArctic AB has a successful business model that focuses on the development and commercialization of therapeutic solutions for neurodegenerative diseases. The company collaborates closely with leading scientists and experts in the field to develop innovative products. BioArctic also leverages licensing and partnership agreements to acquire new technologies and capabilities and place its products in the market. The FDA approval of Aduhelm in 2021 has demonstrated BioArctic's potential, with the hope that the company's technology will bring further therapies to the market in the future.

What is the BioArctic dividend?

BioArctic pays a dividend of 0 SEK distributed over payouts per year.

How often does BioArctic pay dividends?

The dividend cannot currently be calculated for BioArctic or the company does not pay out a dividend.

What is the BioArctic ISIN?

The ISIN of BioArctic is SE0010323311.

What is the BioArctic WKN?

The WKN of BioArctic is A2H5GS.

What is the BioArctic ticker?

The ticker of BioArctic is BIOA B.ST.

How much dividend does BioArctic pay?

Over the past 12 months, BioArctic paid a dividend of 1.5 SEK . This corresponds to a dividend yield of about 0.73 %. For the coming 12 months, BioArctic is expected to pay a dividend of 13.58 SEK.

What is the dividend yield of BioArctic?

The current dividend yield of BioArctic is 0.73 %.

When does BioArctic pay dividends?

BioArctic pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BioArctic?

BioArctic paid dividends every year for the past 5 years.

What is the dividend of BioArctic?

For the upcoming 12 months, dividends amounting to 13.58 SEK are expected. This corresponds to a dividend yield of 6.48 %.

In which sector is BioArctic located?

BioArctic is assigned to the 'Health' sector.

Wann musste ich die Aktien von BioArctic kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BioArctic from 5/16/2019 amounting to 1.5 SEK, you needed to have the stock in your portfolio before the ex-date on 5/10/2019.

When did BioArctic pay the last dividend?

The last dividend was paid out on 5/16/2019.

What was the dividend of BioArctic in the year 2024?

In the year 2024, BioArctic distributed 0 SEK as dividends.

In which currency does BioArctic pay out the dividend?

The dividends of BioArctic are distributed in SEK.

All fundamentals about BioArctic

Our stock analysis for BioArctic Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioArctic Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.